Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease

Next Previous
Trial Profile

A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Troriluzole (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms T2 Protect AD
  • Sponsors Biohaven Pharmaceutical Holding Company; Biohaven Pharmaceuticals

    • Most Recent Events

    • 20 Jul 2023 Results of post-hoc analyses, examining whether plasma biomarkers (Ab1-40, Ab1-42, total tau, p-tau-181, NfL, and GFAP) predicted 48-week change in cognitive (ADAS-Cog11), global function (CDR-SB), and volumetric MRI (6 cortical regions and 2 whole brain measures) outcomes in this study, presented at the Alzheimer's Association International Conference 2023
    • 15 Feb 2022 Status changed from active, no longer recruiting to completed.
    • 18 Jan 2021 According to a Biohaven Pharmaceutical media release, the company is planning to amend the ongoing long-term extension study of troriluzole in AD for mild AD patients to be able to continue treatment in order to gather additional clinical and biomarker data.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top